Personalized treatment for newly diagnosed AML based on genetics and early response
Part of Blood & lymphatic, Cancer clinical trials.
This trial uses the genetic makeup of your leukemia and how well it responds to the first round of chemotherapy to guide your treatment plan. The goal is to find the best therapy for your specific type of AML, potentially reducing side effects while still being effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with acute myeloid leukemia (AML) confirmed by bone marrow tests.
- You must be between 18 and 59 years old.
- You must have a good performance status (ECOG score 0, 1, or 2), meaning you are able to carry out daily activities with little or no help.
- Your liver, kidney, and heart function must be within a safe range as determined by blood tests and an echocardiogram (heart ultrasound).
- You must not have a subtype of AML called acute promyelocytic leukemia (APL) or core-binding factor AML (CBF-AML).
- You must not have received any prior treatment for AML (except for a few drugs to control cell counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (aclarubicin, azacitidine, and venetoclax) for adults with acute myeloid leukemia (AML) who either cannot have intensive chemotherapy or whose AML has come back after treatment. The goal is to see if this combination is safe and works better.
This trial tests if adjusting chemotherapy based on early signs of leukemia can improve outcomes for people newly diagnosed with acute myeloid leukemia (AML). It might be a good fit if you are starting treatment and have a certain level of leukemia cells in your blood after a few days of therapy.
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
This trial tests whether one initial chemotherapy approach works better than another in people newly diagnosed with high-risk acute myeloid leukemia (AML). You may benefit if your disease is high-risk, and the study will also compare how well the treatments control the leukemia and how safely they work.
This trial tests a combination of three drugs (tretinoin, azacitidine, and venetoclax) for people newly diagnosed with acute myeloid leukemia (AML) who have not yet received chemotherapy. The goal is to see if this combination can help control the leukemia.
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.